June 22, 2021
NanoCarrier, a Japanese developer of micellar nanoparticle-based drugs, said on June 21 that its investigational cancer agent NC-6300 (epirubicin micelle) was awarded fast track review status for the treatment of angiosarcoma, a type of soft tissue sarcoma, by the US...read more